ReviewFrontiers in microbiology2019
Current Animal Models for Understanding the Pathology Caused by the Respiratory Syncytial Virus.
Review in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Pooled it
- Characterization of Bronchiolitis and Vaccine-induced Enhanced Respiratory Disease in Syrian Hamsters Caused by Respiratory Syncytial Virus Infection.The Journal of infectious diseases · 2026Article
- Article
- Early-life respiratory syncytial virus infection and asthma.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Catching our breath: development of interventions and therapies for respiratory syncytial virus.Microbiology and molecular biology reviews : MMBR · 2026Review
- Dual inhibition of intercellular adhesion molecule-1 and nucleolin reduces RSV infection efficiency in human respiratory organoids.Molecular therapy. Nucleic acids · 2026Article
- Gingipain proteases from the bacteriumProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- Experimental Models to Investigate Viral and Cellular Dynamics in Respiratory Viral Co-Infections.Microorganisms · 2025Review
- Article
- The Derivative Difluoroboranyl-Fluoroquinolone "7a" Generates Effective Inhibition Against theCurrent issues in molecular biology · 2025Article
- Lamb Model of RSV Infection.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Visualizing Respiratory Syncytial Virus Replication in Live Mice.Methods in molecular biology (Clifton, N.J.) · 2025Article
- The Development of Animal Models for Respiratory Syncytial Virus (RSV) Infection and Enhanced RSV Disease.Viruses · 2024Review
- Testing pulmonary physiology in ventilated non-human primates.Journal of medical primatology · 2024Article
- Controlled Human Infection Challenge Studies with RSV.Current topics in microbiology and immunology · 2024Review
- Modeling Human Respiratory Syncytial Virus (RSV) Infection: Recent Contributions and Future Directions Using the Calf Model of Bovine RSV Disease.Journal of immunology (Baltimore, Md. : 1950) · 2023Review
- The Impact of Coronavirus Disease 2019 on Viral, Bacterial, and Fungal Respiratory Infections.Clinics in chest medicine · 2023Review
- 3D engineered tissue models for studying human-specific infectious viral diseases.Bioactive materials · 2023Review
- Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
The human respiratory syncytial virus (hRSV) is the main etiologic agent of severe lower respiratory tract infections that affect young children throughout the world, associated with significant morbidity and mortality, becoming a serious public health problem globally. Up to date, no licensed vaccines are available to prevent severe hRSV-induced disease, and the generation of safe-effective vaccines has been a challenging task, requiring constant biomedical research aimed to overcome this ailment. Among the difficulties presented by the study of this pathogen, it arises the fact that there is no single animal model that resembles all aspects of the human pathology, which is due to the specificity that this pathogen has for the human host. Thus, for the study of hRSV, different animal models might be employed, depending on the goal of the study. Of all the existing models, the murine model has been the most frequent model of choice for biomedical studies worldwide and has been of great importance at contributing to the development and understanding of vaccines and therapies against hRSV. The most notable use of the murine model is that it is very useful as a first approach in the development of vaccines or therapies such as monoclonal antibodies, suggesting in this way the direction that research could have in other preclinical models that have higher maintenance costs and more complex requirements in its management. However, several additional different models for studying hRSV, such as other rodents, mustelids, ruminants, and non-human primates, have been explored, offering advantages over the murine model. In this review, we discuss the various applications of animal models to the study of hRSV-induced disease and the advantages and disadvantages of each model, highlighting the potential of each model to elucidate different features of the pathology caused by the hRSV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.